Sebastiani, GD, Galeazzi, M, Tincani, A, Scorza, R, Mathieu, A, Passiu, G, Morozzi, G, Piette, JC, Cervera, R, Houssiau, F, Smolen, J, Nebro, A Fernandez, De Ramon, E, Goral, A Jedryka, Papasteriades, C, Ferrara, GB, Carcassi, C, Bellisai, F, and Marcolongo, R
Our objective was to determine the HLA-DPB1 allele associations of anticardiolipin (aCL) anti-β[sub 2]GPI (aβ[sub 2]GPI) antibodies, and of clinical manifestations of the antiphospholipid syndrome (APS), in systemic lupus erythematosus (SLE). We studied 577 European patients with SLE. aCL and aβ[sub 2]GPI antibodies were measured by ELISA. Molecular typing of HLA-DPB1 locus was performed by polymerase chain reaction-sequence specific oligonucleotide probe (PCR-SSOP) method. aCL showed positive association with -DPB1*1501 (P = 0.005, OR = 7.4), and -DPB1*2301 (P = 0.009, OR 3.3). aβ[sub 2]GPI showed positive association with -DPB1*0301 (P = 0.01, OR = 1.9), and -DPB1*1901 (P = 0.004, OR 8.1). In addition, livedo reticularis was associated with -DPB1*1401, and Raynaud's phenomenon with -DPB1*2001. In conclusion, HLA-DPB1 locus may contribute to the genetic predisposition to develop antiphospholipid antibodies and clinical manifestations of the APS in patients with SLE. [ABSTRACT FROM AUTHOR]